BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23416191)

  • 1. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.
    Chen H; Yang Z; Ding C; Chu L; Zhang Y; Terry K; Liu H; Shen Q; Zhou J
    Eur J Med Chem; 2013 Apr; 62():498-507. PubMed ID: 23416191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).
    Chen H; Yang Z; Ding C; Xiong A; Wild C; Wang L; Ye N; Cai G; Flores RM; Ding Y; Shen Q; Zhou J
    Eur J Med Chem; 2014 Jul; 82():195-203. PubMed ID: 24904966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
    Godse P; Kumar P; Yewalkar N; Deore V; Lohar M; Mundada R; Padgaonkar A; Manohar S; Joshi A; Bhatia D; Desai N; Damre A; Bhonde M; Joshi K; Sharma R; Kumar S
    Anticancer Agents Med Chem; 2013 Nov; 13(9):1460-6. PubMed ID: 24102269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
    Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
    Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
    Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
    Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
    Wang X; He Q; Wu K; Guo T; Du X; Zhang H; Fang L; Zheng N; Zhang Q; Ye F
    Eur J Med Chem; 2019 Oct; 179():218-232. PubMed ID: 31254923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
    Feng KR; Wang F; Shi XW; Tan YX; Zhao JY; Zhang JW; Li QH; Lin GQ; Gao D; Tian P
    Eur J Med Chem; 2020 Sep; 201():112428. PubMed ID: 32603980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
    Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
    Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
    Yu W; Xiao H; Lin J; Li C
    J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, And Evaluation Of Cyanopyridines As Anti-Colorectal Cancer Agents Via Inhibiting STAT3 Pathway.
    Xu L; Shi L; Qiu S; Chen S; Lin M; Xiang Y; Zhao C; Zhu J; Shen L; Zuo Z
    Drug Des Devel Ther; 2019; 13():3369-3381. PubMed ID: 31576111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
    Li N; Ou J; Bao N; Chen C; Shi Z; Chen L; Sun J
    Bioorg Chem; 2020 Nov; 104():104208. PubMed ID: 32919131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
    Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
    Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis and Anticancer Evaluation of New Substituted Thiophene-Quinoline Derivatives.
    Othman DIA; Selim KB; El-Sayed MA; Tantawy AS; Amen Y; Shimizu K; Okauchi T; Kitamura M
    Bioorg Med Chem; 2019 Oct; 27(19):115026. PubMed ID: 31416740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo.
    Liu Z; Wang H; Guan L; Lai C; Yu W; Lai M
    Br J Pharmacol; 2020 Jan; 177(2):298-313. PubMed ID: 31499589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, synthesis, and evaluation of small-molecule signal transducer and activator of transcription 3 inhibitors.
    Shi ZB; Zhao D; Huang YY; Du Y; Cao XR; Gong ZN; Zhao R; Li JX
    Chem Pharm Bull (Tokyo); 2012; 60(12):1574-80. PubMed ID: 23207637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and In Vitro Evaluation of Tetrahydroquinoline Derivatives as Antiproliferative Compounds of Breast Cancer via Targeting the GPER.
    Zacarías-Lara OJ; Méndez-Luna D; Martínez-Ruíz G; García-Sanchéz JR; Fragoso-Vázquez MJ; Bello M; Becerra-Martínez E; García-Vázquez JB; Correa-Basurto J
    Anticancer Agents Med Chem; 2019; 19(6):760-771. PubMed ID: 30451119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors.
    Pallandre JR; Borg C; Rognan D; Boibessot T; Luzet V; Yesylevskyy S; Ramseyer C; Pudlo M
    Eur J Med Chem; 2015 Oct; 103():163-74. PubMed ID: 26352675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines.
    Taniguchi K; Konishi H; Yoshinaga A; Tsugane M; Takahashi H; Nishisaka F; Shishido Y; Asai A
    Sci Rep; 2021 Mar; 11(1):6685. PubMed ID: 33758275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.